Prostaglandin and Cannabinoid Receptors in EoE

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

45 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-07-01

Study Completion Date

2024-11-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate prostaglandin and cannabinoid receptors and their endogenous ligands in eosinophilic esophagitis (EoE). A prostaglandin D2 receptor antagonist has been shown to improve disease symptoms suggesting a regulatory role for bioactive lipids in EoE. Prostaglandin D2 and E2, and endocannabinoids are lipid mediators that govern the functional and inflammatory behavior of immune cells critical for EoE development. The prostaglandin D2 and E2 receptor axis, and the components of the endocannabinoid may be involved in the pathogenesis of EoE.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis

NCT01479231

Gastroesophageal Reflux Disease Eosinophilic Esophagitis Dysphagia

WITHDRAWN PHASE1/PHASE2

The Potential Role of Compounds Derived From Ultra-processed Foods in Pathogenesis of Eosinophilic Esophagitis

NCT06093204

Esophagitis, Eosinophilic

RECRUITING

Local Clinical and Immunological Responses in Eosinophilic Esophagitis (EoE) Patients, Role of Mucosal Barrier Function and Type II Inflammation

NCT07012928

Eosinophilic Esophagitis (EoE)

RECRUITING

Risk Factors and Biomarkers for Diagnosis and Treatment of EoE

NCT01988285

Eosinophilic Esophagitis

ACTIVE_NOT_RECRUITING

Proof of Concept Study of OC000459 in Eosinophilic Esophagitis

NCT01056783

Eosinophilic Esophagitis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Prostaglandin D2 and E2 receptors, and components of the endocannabinoid system (cannabinoid receptors and endocannabinoid-metabolizing enzymes) are examined in mucosal esophageal biopsies and blood leukocytes from EoE patients (acute and in remission), individuals with gastroesophageal reflux and from individuals with no esophageal disease. Expression of these components are compared between all cohorts by polymerase chain reaction, Western blots, flow cytometry and immunohistochemical methods. EoE disease activity is evaluated by determining a symptom score and the number of eosinophils per high-power field (hpf) in histologic sections of mucosal biopsies. Additionally, an Endoscopic Reference Score (EREFS) is used. Disease activity is correlated with cannabinoid/prostaglandin D2 and E2 receptor expression. Blood is collected and immediately processed for flow cytometric experiments. Prostaglandins and endocannabinoids are measured in plasma and esophageal mucosal biopsy samples of all cohorts by mass spectrometry.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Eosinophilic Esophagitis (EoE)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

EoE group

Patients with confirmed eosinophilic esophagitis

Biopsy samples

Intervention Type OTHER

Esophageal mucosal biopsies are collected during gastroscopy

Blood samples

Intervention Type OTHER

Blood will be drawn by venipuncture into citrate- or ethylenediaminetetraacetic acid (EDTA)-containing vacutainer tubes and into serum tubes

GERD group

Patients with gastro-esophageal reﬂux disease

Biopsy samples

Intervention Type OTHER

Esophageal mucosal biopsies are collected during gastroscopy

Blood samples

Intervention Type OTHER

Blood will be drawn by venipuncture into citrate- or ethylenediaminetetraacetic acid (EDTA)-containing vacutainer tubes and into serum tubes

Control group

Individuals with no esophageal disease

Biopsy samples

Intervention Type OTHER

Esophageal mucosal biopsies are collected during gastroscopy

Blood samples

Intervention Type OTHER

Blood will be drawn by venipuncture into citrate- or ethylenediaminetetraacetic acid (EDTA)-containing vacutainer tubes and into serum tubes

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biopsy samples

Esophageal mucosal biopsies are collected during gastroscopy

Intervention Type OTHER

Blood samples

Blood will be drawn by venipuncture into citrate- or ethylenediaminetetraacetic acid (EDTA)-containing vacutainer tubes and into serum tubes

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* diagnosed or suspected EoE or GERD
* without esophageal diseases
* with signed informed consent

Exclusion Criteria

* viral or parasitic diseases (e.g. herpes, candidiasis)
* eosinophilic gastroenteritis, hypereosinophilic syndrome, Crohn's disease
* autoimmune diseases
* unable to give informed consent
* immunosuppressive therapy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes